전립선암 진단 시장 규모, 점유율 및 동향 분석 보고서 : 검사 유형별, 유형별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Prostate Cancer Diagnostics Market Growth & Trends:

The global prostate cancer diagnostics market size is expected to reach USD 13.16 billion by 2030, expanding at a CAGR of 6.4% from 2024 to 2030,according to a new report by Grand View Research, Inc. Supportive government initiatives, increasing disease prevalence across the globe, and a rise in the prevalence of prostate cancer coupled with technological advancements in confirmatory diagnostic tests are the major drivers for this market.

A rise in favorable government initiatives to enhance research associated with a focus on effective diagnosis and treatment is expected to boost market growth during the forecast period. For instance, the National Cancer Institute initiated the study titled 'Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress' (RESPOND). This study is the largest collaboration to research the non-biological and biological factors that are associated with prostate cancer in African-American men. It was launched by the National Institute on Minority Health and NCI and Health Disparities in collaboration with the Prostate Cancer Foundation with a funding of USD 26.0 million.

Researchers from the University of Norfolk and East Anglia along with Norwich University Hospital developed a non-invasive urine test that helps in identifying men that are up to 8 times less likely to need a treatment procedure within 5 years of diagnosis. Technological advancements such as these are also anticipated to impact market potential in the near future.

Additionally, researchers at Karolinska and KTH Institute concluded that the use of artificial intelligence in spatial transcriptomics can aid in the early detection of prostate cancer, thereby, improving clinical diagnosis and treatment. Spatial transcriptomics is a method that usually combines quantitative analysis of active genes and their histology and can aid in effective disease diagnosis.

Prostate Cancer Diagnostics Market Report Highlights:

• Confirmatory tests held the largest market share in 2023. The segment holds largest market share by 66.4%. Confirmatory tests include the PCA3 test, Transrectal Ultrasound (TRUS), and biopsy of the affected portion
• Based on end use, the market is segmented into hospitals, outpatient facilities, home care, and research & manufacturing. In 2023, the Outpatient Facilities segment dominated the market. Outpatient Facilities have revolutionized and developed more comfortable consulting and treatment systems with the acquisition and experience of the licensed physician
• The North American region holds the largest market share owing to rising prevalence and the rise in government initiatives to enhance diagnosis

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Type
  • 1.2.2. Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test Type
  • 2.2.2. Type
  • 2.2.3. End Use
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of prostate cancer
    • 3.2.1.2. Increasing global geriatric population
    • 3.2.1.3. Technological advancements in the field of cancer diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of diagnostics
• 3.3. Prostate Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Prostate Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

• 4.1. Test Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Prostate Cancer Diagnostics Market by Test Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Preliminary Tests
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. PSA Tests
    • 4.4.1.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Free PSA Test
    • 4.4.1.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Total PSA Test
    • 4.4.1.4.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Other Preliminary Tests
    • 4.4.1.5.1 Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Confirmatory Tests
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Pca3 Test
    • 4.4.2.2.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Trans-Rectal Ultrasound
    • 4.4.2.3.1 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. Biopsy Test
    • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Prostate Cancer Diagnostics Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Adenocarcinoma
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Interstitial Cell Carcinoma
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Other
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Prostate Cancer Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. End-use Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Prostate Cancer Diagnostics Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospitals
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Outpatient Facilities
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Home Care
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Research & Manufacturing
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. MDx Health
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Test Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Myriad Genetics, Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Test Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Abbott Laboratories
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Test Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. F. Hoffman-La Roche AG
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Test Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Bayer AG
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Test Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Siemens Healthcare GmbH
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Test Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. OPKO Health, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Test Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Genomic Health.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Test Type benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Pfizer Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Test Type benchmarking
    • 8.3.12.4. Strategic initiatives